Anupam Rasayan Q1 FY27 earnings call filed; revenue rises 36%
ANURAS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Q1 FY27 consolidated total income rose 36% YoY to INR667.5 crores with EBITDA up 35% to INR175 crores at 26% margin. PAT grew 6% to INR51 crores. Management highlighted commercialization of ETFA using flow chemistry (global first), BASQUEVOLT LOI of USD300 million over 10 years, and INR18,000 crores cumulative LOI and contract pipeline. Bliss GVS Pharma acquisition to close by mid-September. EBITDA guidance: 22 to 24 percent consolidated, 24 to 26 percent standalone.
Strong revenue growth and completion of major capex cycle support margin stability and working capital improvement, with acquisitions adding growth optionality.